Remove Capital Market Remove Initial Public Offering Remove Public Trading
article thumbnail

Cooley’s 2022 Life Sciences M&A Year in Review

Cooley M&A

Will 2023 see a resurgence of traditional public M&A deals or will macro factors and the looming threat of regulatory review continue to push biotechnology companies down creative paths? It’s a more challenging market environment right now than we’ve seen in many years,” said Charlie Kim , who co-chairs Cooley’s capital markets practice.

M&A 40
article thumbnail

Cooley’s 2022 Tech M&A Year in Review

Cooley M&A

Newly public tech companies (particularly companies that went public via deSPAC transactions) may find themselves particularly in the crosshairs, given that they as a whole dramatically underperformed the broader market in 2022.

M&A 52